Poland· PL-100422005

Vastaloma

A fulvestrant product containing fulvestrantum, registered in Poland by Alvogen Pharma Trading Europe EOOD. The same ATC class is registered in 17 of our 19 countries.

ATC L02BA03

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedVastalomaATCL02BA03REGISTER NO.PL-100422005PACKS LISTED3CHECKEDSeptember 27, 2026

Where it is registered

Fulvestrant is registered in 17 of 19 countries.

Countries holding a registration under ATC L02BA03 (fulvestrant), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 9 of them publish a price we can compare per daily dose

Fulvestrant · ATC L02BA03

17 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Germany
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Sweden
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of fulvestrant costs, country by country.

Normalised to the WHO defined daily dose (16.7 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Fulvestrant · price per daily dose (16.7 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$13.25
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

URPL (Poland)
Active substance
Fulvestrantum
Manufacturer
Alvogen Pharma Trading Europe EOOD
Country
Poland (PL)
ATC code
L02BA03
ATC class
Fulvestrant
Defined daily dose
16.7 mg, P
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 3

  • gtin
    05909991441586
  • gtin
    05909991441593
  • gtin
    05909991441609

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

110 interactions on record for fulvestrant.

Graded by severity as the source publishes them — 1 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Fulvestrant · interactions on record

110 records

  • 1 moderate
  • 109 info

Most severe, free to view

  • Omacetaxine mepesuccinateL01XX40moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Fulvestrant in 15 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All fulvestrant products

Authorised across Europe · EMA

The same active substance is authorised in 30 EEA countries. Names it is sold under:

  • Austria · Fulvestrant +pharma, Fulvestrant Accord
  • Belgium · Fulvestrant Accord, Fulvestrant Eugia
  • Bulgaria · Fulvestrant Ever Pharma, Fulvestrant Pharmascience
  • Cyprus · Fulvestrant Accord, Fulvestrant Rompharm
  • Czechia · Fulvestrant Accord, Fulvestrant Ever Pharma
  • Germany · Fulvestrant 1 A Pharma, Fulvestrant Abz
  • Denmark · Fulvestrant "stada", Fulvestrant Accord
  • Estonia · Fulvestrant Accord, Fulvestrant Aliud
  • Spain · Afultrant, Ambiful
  • Finland · Fulvestrant Accord, Fulvestrant Ever Pharma
  • France · Fulvestrant, Fulvestrant Accord
  • United Kingdom (Northern Ireland) · Fulvestrant Accord Healthcare, Fulvestrant Dr. Reddy's
  • Greece · Fulvestrant Accord, Fulvestrant Demo
  • Croatia · Fulvestrant Accord, Fulvestrant Aptapharma
  • Hungary · Fulvestrant Aptapharma, Fulvestrant Elc
  • Ireland · Fulvestrant Accord Healthcare Ireland, Fulvestrant Ever Pharma
  • Iceland · Faslodex, Fulvestrant Accord
  • Italy · Fulvestrant Accord, Fulvestrant Aurobindo
  • Liechtenstein · Faslodex, Fulvestrant Mylan
  • Lithuania · Fulvestrant Aliud, Fulvestrant Orion
  • Luxembourg · Fulvestrant Teva
  • Latvia · Fulvestrant Aliud, Fulvestrant Stada
  • Malta · Fulvestrant Ever Pharma
  • Netherlands · Fulvestrant, Fulvestrant Accord
  • Norway · Faslodex, Fulvestrant Accord
  • Portugal · Ambiful, Cykostra
  • Romania · Falvax, Fulvestrant Accord
  • Sweden · Fulvestrant Accord, Fulvestrant Ever Pharma
  • Slovenia · Fulvestrant Accord, Fulvestrant Aptapharma
  • Slovakia · Fulvestrant Accord, Fulvestrant Ever Pharma

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/d7a83c72-cf6f-42dd-91e6-659a12a323e6
GET /v1/drugs/d7a83c72-cf6f-42dd-91e6-659a12a323e6?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Roztwór do wstrzykiwań",
  "source": "urpl",
  "strength": "250 mg/5 ml",
  "packaging": "05909991441586 ¦ Rp ¦ 138211\n1 amp.-strzyk.  z zabezpieczeniem\n05909991441593 ¦ Rp ¦ 138212\n2 amp.-strzyk.  z zabezpieczeniem\n05909991441609 ¦ Rp ¦ 138213\n6 amp.-strzyk.  z zabezpieczeniem",
  "substance": "Fulvestrantum",
  "common_name": "Fulvestrantum",
  "pl_product_id": "100422005",
  "pozwolenie_nr": "26127",
  "auth_procedure": "DCP",
  "authorisation_validity": "2023-09-29"
}

See everything about fulvestrant.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.